Research programme: human monoclonal antibodies - Vaccinogen

Drug Profile

Research programme: human monoclonal antibodies - Vaccinogen

Alternative Names: Oncavert®

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Vaccinogen
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Adenocarcinoma

Most Recent Events

  • 16 Jun 2016 Vaccinogen files for patent protection for human monoclonal antibodies
  • 16 Jun 2016 Research programme: human monoclonal antibodies - Vaccinogen is available for licensing as of 16 Jun 2016. http://www.vaccinogeninc.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top